Skip Navigation LinksHome > March 2014 - Volume 34 - Issue 3 > TOPICAL NEPAFENAC AFTER INTRAVITREAL INJECTION: A Prospectiv...
doi: 10.1097/IAE.0b013e3182a0e611
Original Study

TOPICAL NEPAFENAC AFTER INTRAVITREAL INJECTION: A Prospective Double-Masked Randomized Controlled Trial

Ulrich, J. Niklas MD

Collapse Box


Purpose: To evaluate if a single drop of nepafenac can reduce the ocular discomfort after intravitreal injections compared with placebo.

Methods: One hundred and twenty patients undergoing intravitreal injections of bevacizumab or ranibizumab received a drop of nepafenac or placebo (Systane Ultra) after the injection in a prospective, double-masked, randomized controlled design. Patients rated their pain levels from 0 to 3 (no pain, mild pain, moderate pain, severe pain) at 1 hour, 6 hours, and 24 hours after the procedure.

Results: Statistically significant reduction of postinjection pain with nepafenac was noted 6 hours after the injection when compared with placebo (0.8 ± 0.6 [standard deviation] vs. 1.3 ± 0.8, P < 0.001) with similar trends at 1 hour (1.1 ± 0.7 vs. 1.3 ± 0.7, P = 0.12) and 24 hours (0.3 ± 0.5 vs. 0.5 ± 0.6, P = 0.15).

Conclusion: A single drop of nepafenac is effective in reducing discomfort after intravitreal injections.

© 2014 by Ophthalmic Communications Society, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.